What data exist regarding treatment for conjunctivitis from dupilumab in children <5 years of age?

The long-term dupilumab study in young children (Paller et al., PMID 41926052) showed 19% conjunctivitis (n = 121), all are mild to moderate and did not require treatment. Median time of resolution was 8 days. Therefore, if a young child with more severe conjunctivitis due to dupilumab lasting longe...

The incidence of conjunctivitis in children under 5 years old receiving dupilumab ranges from 5% to 19% in clinical trials and real-world studies, with cases typically being mild and self-limited, lasting on average around 8 days (van der Rijst et al., PMID 40103206, Paller et al., PMID 41926052). I...